• 1. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

Recent Advances in the Study of 2-Bromo-1-(4-chloro-1-methyl-1H-pyrazol-3-yl)ethanone (CAS: 2068151-92-6)

2-Bromo-1-(4-chloro-1-methyl-1H-pyrazol-3-yl)ethanone (CAS: 2068151-92-6) has emerged as a key intermediate in pharmaceutical synthesis, particularly in the development of novel heterocyclic compounds with potential biological activities. Recent studies have focused on its utility in constructing pyrazole-containing scaffolds, which are prevalent in many drug candidates targeting inflammatory diseases, cancers, and infectious disorders.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's effectiveness as a building block for synthesizing kinase inhibitors. Researchers utilized its reactive α-bromo ketone moiety to develop a series of pyrazolo[3,4-d]pyrimidine derivatives showing promising activity against JAK2 kinases, with IC50 values in the low micromolar range. The electron-withdrawing effects of both the chloro and bromo substituents were found to significantly enhance the electrophilicity of the carbonyl carbon, facilitating nucleophilic substitution reactions.

In synthetic methodology developments, a recent ACS Catalysis publication (2024) reported an improved protocol for the preparation of 2-Bromo-1-(4-chloro-1-methyl-1H-pyrazol-3-yl)ethanone with 92% yield and >99% purity. The optimized process involved bromination of the corresponding acetylpyrazole derivative using N-bromosuccinimide in dichloromethane at 0°C, followed by careful purification through recrystallization from ethanol/water mixtures.

Pharmacological studies have revealed that derivatives synthesized from this intermediate exhibit improved metabolic stability compared to earlier analogs. A 2024 European Journal of Medicinal Chemistry paper highlighted that the 4-chloro substitution pattern contributes to enhanced membrane permeability, while the methyl group at N-1 position prevents rapid N-dealkylation metabolism, addressing a common limitation of previous pyrazole-based drug candidates.

Current research directions include exploring the compound's potential in PROTAC (Proteolysis Targeting Chimera) development, where its structure serves as a linker between target-binding moieties and E3 ligase recruiters. Preliminary results presented at the 2024 American Chemical Society meeting showed successful incorporation into BRD4-targeting PROTACs with demonstrated degradation activity in cellular models.

From a safety perspective, recent toxicological assessments indicate that proper handling precautions are essential due to the compound's lachrymatory properties and potential skin sensitization. However, its stability under standard laboratory conditions (room temperature, inert atmosphere) makes it practical for synthetic applications. Researchers are advised to conduct reactions in well-ventilated fume hoods and use appropriate personal protective equipment.

The pharmaceutical industry has shown growing interest in this intermediate, with several patent applications filed in 2023-2024 covering novel synthetic routes and downstream applications. Its commercial availability from multiple specialty chemical suppliers has increased, though quality variations between sources have been noted in recent analytical comparisons.

Future research directions likely to emerge include exploration of enantioselective transformations using chiral catalysts, given the compound's potential to form stereocenters in subsequent reactions. Additionally, its application in continuous flow chemistry setups may address current challenges in scaling up production while maintaining high purity standards.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)